22:54 , Nov 17, 2017 |  BioCentury  |  Finance

Stepwise progress

After six years and four Phase I trials ImmusanT Inc. has finally nailed down the optimal dose regimen for celiac disease vaccine Nexvax2 and is ready to take the leap into Phase IIb testing with...
07:00 , Mar 26, 2012 |  BioCentury  |  Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance. The...